A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

NCT01772472 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1486

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: trastuzumab
DRUG: trastuzumab emtansine

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]